Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience

Hamza Hashmi, MD, Jeffrey Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Lia Perez, MD, Farhad Khimani, MD, Michael Nieder, MD, Hany Elmariah, MD MS, Joseph Pidala, MD, Nelli Bejanyan, MD, Alan F. List, MD, Claudio Anasetti, MD, Taiga Nishihori, MD

Blood (2019) 134 (Supplement_1): 5739.

https://doi.org/10.1182/blood-2019-128985

Published: 2019

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

Chetasi Talati, MD, Ryan J Caddell, PharmD, BCOP, Katherine Tobon, PharmD, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Eric Padron, MD, Hugo F. Fernandez, MD, Alan F. List, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 2636.

https://doi.org/10.1182/blood-2019-129166

Published: 2019

Journal Articles

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hannah Asghari, MD BS, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 1357.

https://doi.org/10.1182/blood-2019-128958

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

Yumeng Zhang, MD, Hannah H Asghari, MD, Onyee Chan, MD, Dasom Lee, MD, Martine Extermann, MD, Najla Al Ali, M.Sc, Yehuda E. Deutsch, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, David A Sallman, MD, Chetasi Talati, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 1368.

https://doi.org/10.1182/blood-2019-127772

Published: 2019

Journal Articles

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Richard Thomas T. Maziarz, MD, Mrinal M. Patnaik, MDMBBS, Bart L Scott, MD, Sanjay R. Mohan, MD MSCI, Abhinav Deol, MD, Scott D. Rowley, MD, Dennis Kim, MD, Kelly Haines, Gaetano J Bonifacio, MD, Patrice Rine, Das Purkayastha, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 662.

https://doi.org/10.1182/blood-2018-99-113582

Published: 2018

Journal Articles

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Chetasi Talati, MD, Aaron D Goldberg, MD PhD, Pinkal Desai, MD MPH, Onyee Chan, MD, Christopher Famulare, MS, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Hugo F. Fernandez, MD, Yehuda E. Deutsch, MD, Eric Padron, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, MD, Martin S. Tallman, MD, David A Sallman, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2018-99-117412

Published: 2018

Journal Articles

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Yehuda E. Deutsch, MD, Justin T Presutto, PharmD, MBA, Amanda Brahim, Pharm.D., Jyotishankar Raychaudhuri, MD, Marco Andres Ruiz, MD, Jose Sandoval-Sus, MD, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2018-99-115682

Published: 2018

Journal Articles

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

Jun Yin, PhD, Geoffrey L. Uy, MD, Betsy Laplant, MS, Elizabeth Storrick, Guido Marcucci, Hugo F. Fernandez, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD, Richard A. Larson, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD

Blood (2018) 132 (Supplement 1): 1386.

https://doi.org/10.1182/blood-2018-99-113902

Published: 2018

Journal Articles

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Lia Perez, MD, Hugo F. Fernandez, MD, Farhad Khimani, MBBS, Ernesto Ayala, MD, Mohamed A Kharfan-Dabaja, MD, Asmita Mishra, MD, Leonel Ochoa, MD, Brian C. Betts, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD

Blood (2017) 130 (Supplement 1): 1985.

https://doi.org/10.1182/blood.V130.Suppl_1.1985.1985

Published: 2017

Journal Articles

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Ryan James Caddell, PharmD, Braydon Schaible, MPH, Zhenjun Ma, PhD, Elizabeth Dimaggio, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Claudio Anasetti, MD, Ernesto Ayala, MD, Brian C. Betts, MD, Mohamed A. Kharfan-Dabaja, MD, Frederick L. Locke, MD, Taiga Nishihori, MD, Joseph A. Pidala, MD, Hugo F. Fernandez, MD, Asmita Mishra, MD

Blood (2016) 128 (22): 3486.

https://doi.org/10.1182/blood.V128.22.3486.3486

Published: 2016

Journal Articles

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3 -Itd-Mutated Acute Myeloid Leukemia (AML)

Richard T. Maziarz, MD, Mrinal M Patnaik, MBBS, Bart L. Scott, MD, Sanjay R. Mohan, MD, Abhinav Deol, MD, Scott D. Rowley, MD FACP, Dennis Dong Hwan Kim, MD PhD, Kelly Haines, BS, Gaetano Bonifacio, MD, Patrice Rine, Hugo F. Fernandez, MD

Blood (2016) 128 (22): 2248.

https://doi.org/10.1182/blood.V128.22.2248.2248

Published: 2016

Journal Articles

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

Chezi Ganzel, Larry D. Cripe, MD, Zhouxin Sun, Hugo F. Fernandez, MD, Peter A Cassileth, MD, Dan Douer, MD, Jacob M. Rowe, MD, Elisabeth Paietta, PhD, Michael O'Connell, Peter H Wiernik, John M. Bennett, MD, Mark R Litzow, MD, Selina Luger, MD, Hillard M. Lazarus, MD, Martin S. Tallman, MD

Blood (2015) 126 (23): 1315.

https://doi.org/10.1182/blood.V126.23.1315.1315

Published: 2015

Journal Articles

A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML

Marlise R. Luskin, MD, Phyllis Gimotty, PhD, Catherine Smith, Alison Loren, MD MS, Maria Figueroa, MD, Jenna Harrison, Zhuoxin Sun, PhD, Martin S Tallman, MD, Elisabeth Paietta, PhD, Mark R Litzow, MD, Ross L. Levine, MD, Hugo F. Fernandez, MD, Selina Luger, MD, Martin Carroll, MD, Stephen Master, MD PhD, Gerald Wertheim, MD PhD

Blood (2015) 126 (23): 2591.

https://doi.org/10.1182/blood.V126.23.2591.2591

Published: 2015

Journal Articles

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Yi-Bin Chen, MD, Jennifer Le-Rademacher, PhD, Deidre Marie Kiefer, MPH, Mehdi Hamadani, MD, John F. DiPersio, MD PhD, Mark R Litzow, MD, Michael Craig, MD, Mitchell E. Horwitz, MD, Andrew Artz, MD MS, Brian McClune, DO, Edmund K Waller, MD PhD, Hugo F. Fernandez, MD, Hien Kim Duong, MD, Hati Kobusingye, Mandi Proue, MPH, Rebecca J. Drexler, MPH, Mary M. Horowitz, MD MS, John P. Miller, MD PhD, Steven M. Devine, MD

Blood (2015) 126 (23): 389.

https://doi.org/10.1182/blood.V126.23.389.389

Published: 2015

Journal Articles

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Mohamed A. Kharfan-Dabaja, MD, Rami S. Komrokji, MD, Qing Zhang, PhD, David Sallman, MD, Asmita Mishra, MD, Najla H. Al Ali, BDS, MSc, Taiga Nishihori, MD, Teresa Field, MD, PhD, Karma Z Salem, MD, Janelle Perkins, PharmD, Ling Zhang, MD, Lynn C. Moscinski, MD, Hugo F. Fernandez, MD, Jeffrey E Lancet, MD, Alan F. List, MD, Claudio Anasetti, MD, Eric Padron, MD

Blood (2015) 126 (23): 4382.

https://doi.org/10.1182/blood.V126.23.4382.4382

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

Kendra L Sweet, MD MS, Jeffrey E Lancet, MD, Ryan Hillgruber, BS, Megan Melody, MS, Amina Llishi, Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Teresa Field, MD, PhD

Blood (2015) 126 (23): 4388.

https://doi.org/10.1182/blood.V126.23.4388.4388

Published: 2015

Journal Articles

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Michael T Tees, MD MPH, Brian C Betts, MD, Hugo F Fernandez, MD, Ryan Hillgruber, Ernesto Ayala, MD, Teresa Field, MD PhD, Mohamed A Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD, Marcie L Riches, MD MS

Blood (2014) 124 (21): 2475.

https://doi.org/10.1182/blood.V124.21.2475.2475

Published: 2014

NARROW

Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3 -Itd-Mutated Acute Myeloid Leukemia (AML)

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only